Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, to market a generic equivalent of Toviaz® Extended-Release Tablets, 4 mg and 8 mg, of Pfizer Inc. The product will be manufactured at Lupin’s facility in Goa, India.
source https://www.pharmatutor.org/pharma-news/2023/lupin-receives-fda-nod-for-fesoterodine-fumarate-extended-release-tablets
No comments:
Post a Comment